Tracey Lodie appointed Chief Scientific Officer of Quell Therapeutics

pharmafile | August 25, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Quell Therapeutics has announced the appointment of Tracey Lodie as Chief Scientific Officer.

Dr Lodie brings to Quell more than 20 years of experience in the biopharmaceutical industry focused on the discovery and development of cell therapies and novel biologics in the areas of autoimmunity, transplant biology, and immune-oncology.

Dr Lodie joins Quell from Gamida Cell, a clinical-stage, Nasdaq-listed cell therapy company, where she served as CSO with responsibility for strategic oversight of its entire cell therapy pipeline.

Related Content

No items found

Latest content